Literature DB >> 22481406

In cancer drug resistance, germline matters too.

Emily H Cheng, Charles L Sawyers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22481406     DOI： 10.1038/nm.2725

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  15 in total

1.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Authors:  Anthony Letai; Michael C Bassik; Loren D Walensky; Mia D Sorcinelli; Solly Weiler; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

2.  Converting cancer therapies into cures: lessons from infectious diseases.

Authors:  Michael S Glickman; Charles L Sawyers
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

3.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Authors:  King Pan Ng; Axel M Hillmer; Charles T H Chuah; Wen Chun Juan; Tun Kiat Ko; Audrey S M Teo; Pramila N Ariyaratne; Naoto Takahashi; Kenichi Sawada; Yao Fei; Sheila Soh; Wah Heng Lee; John W J Huang; John C Allen; Xing Yi Woo; Niranjan Nagarajan; Vikrant Kumar; Anbupalam Thalamuthu; Wan Ting Poh; Ai Leen Ang; Hae Tha Mya; Gee Fung How; Li Yi Yang; Liang Piu Koh; Balram Chowbay; Chia-Tien Chang; Veera S Nadarajan; Wee Joo Chng; Hein Than; Lay Cheng Lim; Yeow Tee Goh; Shenli Zhang; Dianne Poh; Patrick Tan; Ju-Ee Seet; Mei-Kim Ang; Noan-Minh Chau; Quan-Sing Ng; Daniel S W Tan; Manabu Soda; Kazutoshi Isobe; Markus M Nöthen; Tien Y Wong; Atif Shahab; Xiaoan Ruan; Valère Cacheux-Rataboul; Wing-Kin Sung; Eng Huat Tan; Yasushi Yatabe; Hiroyuki Mano; Ross A Soo; Tan Min Chin; Wan-Teck Lim; Yijun Ruan; S Tiong Ong
Journal:  Nat Med       Date:  2012-03-18       Impact factor: 53.440

Review 4.  Promoting apoptosis as a strategy for cancer drug discovery.

Authors:  Stephen W Fesik
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

5.  Bim is a suppressor of Myc-induced mouse B cell leukemia.

Authors:  Alexander Egle; Alan W Harris; Philippe Bouillet; Suzanne Cory
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

6.  Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.

Authors:  Ryoko Kuribara; Hiroaki Honda; Hirotaka Matsui; Tetsuharu Shinjyo; Takeshi Inukai; Kanji Sugita; Shinpei Nakazawa; Hisamaru Hirai; Keiya Ozawa; Toshiya Inaba
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

Review 7.  IAP-targeted therapies for cancer.

Authors:  E C LaCasse; D J Mahoney; H H Cheung; S Plenchette; S Baird; R G Korneluk
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

8.  Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction.

Authors:  Miriam Erlacher; Verena Labi; Claudia Manzl; Günther Böck; Alexandar Tzankov; Georg Häcker; Ewa Michalak; Andreas Strasser; Andreas Villunger
Journal:  J Exp Med       Date:  2006-12-18       Impact factor: 14.307

9.  BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Authors:  Daniel B Costa; Balázs Halmos; Amit Kumar; Susan T Schumer; Mark S Huberman; Titus J Boggon; Daniel G Tenen; Susumu Kobayashi
Journal:  PLoS Med       Date:  2007-10       Impact factor: 11.069

10.  Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.

Authors:  Mark S Cragg; Junya Kuroda; Hamsa Puthalakath; David C S Huang; Andreas Strasser
Journal:  PLoS Med       Date:  2007-10       Impact factor: 11.069
View more
  11 in total

1.  Single nucleotide polymorphisms (SNPs) in non-small cell lung cancer (NSCLC) patients.

Authors:  Rafael Rosell; Jia Wei
Journal:  Oncologist       Date:  2012-09-26

Review 2.  The pharmacogenomics of drug resistance to protein kinase inhibitors.

Authors:  Nancy K Gillis; Howard L McLeod
Journal:  Drug Resist Updat       Date:  2016-07-05       Impact factor: 18.500

3.  PUMA and BIM are required for oncogene inactivation-induced apoptosis.

Authors:  Gregory R Bean; Yogesh Tengarai Ganesan; Yiyu Dong; Shugaku Takeda; Han Liu; Po M Chan; Yafen Huang; Lewis A Chodosh; Gerard P Zambetti; James J-D Hsieh; Emily H-Y Cheng
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

4.  Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer.

Authors:  Raghu Gogada; Neelu Yadav; Junwei Liu; Shaohua Tang; Dianmu Zhang; Andrea Schneider; Athul Seshadri; Leimin Sun; C Marcelo Aldaz; Dean G Tang; Dhyan Chandra
Journal:  J Biol Chem       Date:  2012-11-14       Impact factor: 5.157

5.  NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.

Authors:  Ching-Feng Chiu; Yi-Wen Chang; Kuang-Tai Kuo; Yu-Shiuan Shen; Chien-Ying Liu; Yang-Hao Yu; Ching-Chia Cheng; Kang-Yun Lee; Feng-Chi Chen; Min-Kung Hsu; Tsang-Chih Kuo; Jui-Ti Ma; Jen-Liang Su
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

Review 6.  Epidermal growth factor receptor mutations in lung adenocarcinoma.

Authors:  Markus D Siegelin; Alain C Borczuk
Journal:  Lab Invest       Date:  2013-12-30       Impact factor: 5.662

7.  Network-based drug discovery by integrating systems biology and computational technologies.

Authors:  Elaine L Leung; Zhi-Wei Cao; Zhi-Hong Jiang; Hua Zhou; Liang Liu
Journal:  Brief Bioinform       Date:  2012-08-09       Impact factor: 11.622

Review 8.  Pharmacogenomics in oncology care.

Authors:  Kelly K Filipski; Leah E Mechanic; Rochelle Long; Andrew N Freedman
Journal:  Front Genet       Date:  2014-04-08       Impact factor: 4.599

9.  A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Authors:  K E Ware; T K Hinz; E Kleczko; K R Singleton; L A Marek; B A Helfrich; C T Cummings; D K Graham; D Astling; A-C Tan; L E Heasley
Journal:  Oncogenesis       Date:  2013-03-25       Impact factor: 7.485

10.  The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.

Authors:  Benjamin D Ferguson; Ren Liu; Cleo E Rolle; Yi-Hung Carol Tan; Valery Krasnoperov; Rajani Kanteti; Maria S Tretiakova; Gustavo M Cervantes; Rifat Hasina; Robyn D Hseu; A John Iafrate; Theodore Karrison; Mark K Ferguson; Aliya N Husain; Leonardo Faoro; Everett E Vokes; Parkash S Gill; Ravi Salgia
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.